Introduction
Approximately 20% of children with acute lymphoblastic leukemia (ALL) still suffer from relapse and may benefit from improved risk stratification and adapted treatment strategies. In this context, the influence of IKZF1 gene aberrations on therapeutic outcome has received much attention in recent investigations. IKZF1 encodes for Ikaros, a zinc-finger transcription factor family member, which functions sequencespecific in transcriptional regulation and chromatin remodeling and is required for the development of all lymphoid lineages [1] [2] [3] . Somatic aberrations of IKZF1 have recurrently been observed in precursor B-cell ALL (pB-ALL) -most frequently in those carrying a BCR/ABL rearrangement -and have been shown to confer a poor treatment outcome [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] . However, aberrations of IKZF1 were also found to associate with additional genetic alterations recurrently observed in childhood ALL, such as JAK mutations and translocations involving the chemokine receptor like factor 2 (CRLF2) gene 4, 7, [14] [15] [16] [17] [18] .
Juxtaposition of CRLF2 to the IgH@ enhancer or the P2RY8 promoter lead to elevated expression of wild-type CRLF2 in ALL and has been shown to exert a negative prognostic impact on outcome 17, 18 . However, the prognostic relevance seems to be treatment-dependent and it is not clear yet whether the prognostic impact of IKZF1 is independent of these concurrent lesions 19 .
In the present study, we assessed the prognostic role of IKZF1 deletions in a large cohort of 694 pediatric ALL patients treated according to the ALL-BFM 2000 protocol.
Design and Methods

Patients
In accordance with institutional review board regulations, clinical samples were obtained from children with ALL before treatment. The study was approved by the institutional review board of the Hannover Medical School, Hannover, Germany, and informed consent obtained from patients and/or their legal guardians in accordance with the 20 . SR patients were MRD-negative on both TP and HR patients had MRD levels of ≥10 -3 at TP2. MRD-IR patients had positive MRD detection at either one or both time points but at a level of <10 -3 at TP2. Patients with prednisone poor-response (PR; ≥ 1000 leukemic blood blasts / µ l on treatment day 8) or induction failure (≥5% leukemic blasts in the bone marrow, BM) or positivity for chromosomal translocations t(9;22)(q34;q11) or t(4;11)(q21;q23) or their molecular equivalents (BCR/ABL or MLL/AF4 rearrangement) were stratified into the HR group, independent of MRD.
Consecutively enrolled patients from the ALL-BFM 2000 study population with sufficient spare leukemic DNA available were included in our present study (Supplementary Table   1 ). BM or peripheral blood specimens had to contain more than 80% blasts, as assessed morphologically before gradient centrifugation.
Multiplex ligation-dependent probe amplification (MLPA) analysis
Recently, it was shown that MLPA is ideal for rapid high-throughput testing of large cohorts with a view to establish incidence and prognostic significance of certain gene aberrations 23 . MLPA analysis was performed using the MLPA SALSA kit P335-A3 ALL- Figure 2 ). 
Statistical analysis
Results and Discussion
Genetic aberrations in IKZF1 were screened in diagnostic specimens of 694 ALL patients and IKZF1 deletions were detected in 84 out of 694 samples (12%) ( Table 1 ).
This frequency is within the range of abundances reported in other cohorts before 7,9,13 .
Twenty-nine of these deletions covered the whole gene (35%), while 55 were focal deletions (65%). As described previously, focal lesions detected were mainly Δ4-7 (23 cases, 42%) and Δ2 -7 (4 cases, 7%) deletions (Table 1 and Supplementary Figure   2 Comparing leukemic and clinical characteristics of patients with and without IKZF1 deletion, no significant differences were observed concerning sex, age or presence of an MLL/AF4 rearrangement ( Table 2 ). There was a positive association of IKZF1 Most studies published so far focused on pB-ALL, and we also see a significant association of IKZF1 deletions with the pB-ALL phenotype. However, our cohort incorporated a total of 116 T-ALL patients, 6 of which showed an IKZF1 deletion (5.2%).
Out of the six T-ALL IKZF1-deleted patients, one was treated in the SR group, while the others were HR patients. The SR patient is in CR, as are two of the HR patients, while the other three died (only one after a relapse).
Whereas no significant association of IKZF1 status with PR was observed, the presence of IKZF1 deletions was significantly more frequent in MRD-HR patients as compared to IKZF1 deletions were repeatedly reported to confer an increased risk of relapse and poor outcome in selected cohorts 6, 9 and, recently, in an unselected cohort of 131 pB-ALL cases 12, 13 . Here, we present data on the prognostic relevance of IKZF1 in a large set of nearly 700 patients uniformly treated on the MRD-based ALL-BFM 2000 protocol and were able to show that IKZF1 status exerts additive value as a prognostic factorespecially in the IR group in which still the majority of relapses occurs. Therefore, the assessment of IKZF1 status may contribute to a molecular-based stratification algorithm aiming at improving outcome for children suffering from ALL. However, more work has to be done to elucidate the molecular differences between IKZF1-deleted leukemias of patients who relapse and those who don't. From our perspective, this is a prerequisite for an application of the IKZF1 status in clinical decision making. Other focal deletion 28 51 1 MLPA kit P202-A1 contains additional markers, compared to kit P335-A3, identical markers are highlighted in bold. Each row represents one patient, each coloured lane represents a deletion in the respective exon. Light red deletions are heterozygous, dark red deletions are homozygous and light pink deletions are subclonal. In one subclonal sample, results were discordant between P335 and P202, as indicated. Of the six un-validated samples four had a Δ1-8, one a Δ4-7 and one a Δ5-7 deletion in P335. 
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